pamidronic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
calcium metabolism regulator, pharmaceutical aid	2048	40391-99-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: pamidronic acid pamidronate disodium pamidronate pamidronate disodium hydrate	An aminobisphosphonate that inhibits BONE RESORPTION and is used for the treatment of osteolytic lesions, bone pain, and severe HYPERCALCEMIA associated with malignancies. Molecular weight: 235.07 Formula: C3H11NO7P2 CLOGP: -4.32 LIPINSKI: 1 HAC: 8 HDO: 6 TPSA: 161.31 ALOGS: -1.17 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

pamidronic acid
pamidronate disodium
pamidronate
pamidronate disodium hydrate

An aminobisphosphonate that inhibits BONE RESORPTION and is used for the treatment of osteolytic lesions, bone pain, and severe HYPERCALCEMIA associated with malignancies.

Molecular weight: 235.07
Formula: C3H11NO7P2
CLOGP: -4.32
LIPINSKI: 1
HAC: 8
HDO: 6
TPSA: 161.31
ALOGS: -1.17
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
60	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	46 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	5.47 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	1 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	1.80 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2.50 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.70 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	32 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Oct. 31, 1991	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Osteonecrosis of jaw	753.34	18.26	273	11634	34850	63442265
Osteonecrosis	704.12	18.26	237	11670	24293	63452822
Bone disorder	239.27	18.26	104	11803	21222	63455893
Tooth extraction	216.62	18.26	79	11828	10185	63466930
Plasma cell myeloma	168.83	18.26	97	11810	35808	63441307
Atypical femur fracture	166.12	18.26	55	11852	5317	63471798
Sequestrectomy	160.35	18.26	36	11871	790	63476325
Bone debridement	145.23	18.26	27	11880	218	63476897
Malignant neoplasm progression	118.11	18.26	108	11799	82013	63395102
Infusion site coldness	116.60	18.26	22	11885	194	63476921
Debridement	111.73	18.26	29	11878	1189	63475926
Gamma-glutamyltransferase decreased	107.97	18.26	22	11885	298	63476817
Metastases to bone	104.72	18.26	59	11848	20960	63456155
Exposed bone in jaw	98.71	18.26	32	11875	2893	63474222
Bone sequestrum	97.01	18.26	27	11880	1447	63475668
Actinomycosis	96.32	18.26	25	11882	1025	63476090
Pain in jaw	90.95	18.26	71	11836	43425	63433690
Femur fracture	86.96	18.26	68	11839	41688	63435427
Hypocalcaemia	82.45	18.26	59	11848	31654	63445461
Osteomyelitis	80.79	18.26	54	11853	25966	63451149
Bone pain	78.78	18.26	72	11835	54569	63422546
Infusion site induration	78.66	18.26	22	11885	1200	63475915
Impaired healing	74.62	18.26	94	11813	102448	63374667
Cardiac output decreased	74.16	18.26	20	11887	952	63476163
Post-traumatic neck syndrome	67.19	18.26	22	11885	2052	63475063
Vasodilatation	64.08	18.26	22	11885	2373	63474742
Toothache	62.39	18.26	41	11866	19158	63457957
Vein disorder	60.65	18.26	26	11881	5115	63472000
Bone lesion excision	54.60	18.26	9	11898	32	63477083
Jaw disorder	50.07	18.26	23	11884	5326	63471789
Jaw operation	48.79	18.26	14	11893	838	63476277
Infusion site haemorrhage	48.02	18.26	22	11885	5064	63472051
Retinal detachment	47.66	18.26	23	11884	5946	63471169
Mean cell haemoglobin decreased	47.63	18.26	22	11885	5157	63471958
Spinal pain	47.48	18.26	30	11877	13109	63464006
Osteitis	43.43	18.26	18	11889	3256	63473859
Urine odour abnormal	43.24	18.26	22	11885	6367	63470748
Abscess jaw	41.92	18.26	14	11893	1388	63475727
Stress fracture	41.41	18.26	23	11884	7940	63469175
Mineral metabolism disorder	40.85	18.26	6	11901	7	63477108
Wound treatment	40.37	18.26	9	11898	191	63476924
Osteotomy	38.81	18.26	9	11898	229	63476886
Hypercalcaemia	38.24	18.26	36	11871	28286	63448829
Osteosclerosis	37.27	18.26	17	11890	3871	63473244
Peripheral coldness	37.16	18.26	25	11882	12140	63464975
Pathological fracture	36.57	18.26	22	11885	8812	63468303
Incontinence	35.75	18.26	24	11883	11608	63465507
Fistula	35.73	18.26	23	11884	10370	63466745
Tibia fracture	35.73	18.26	18	11889	5102	63472013
Blood creatinine decreased	34.37	18.26	18	11889	5527	63471588
Wound closure	33.44	18.26	7	11900	109	63477006
Bone lesion	33.38	18.26	18	11889	5863	63471252
Poor venous access	32.77	18.26	25	11882	14760	63462355
Skin sensitisation	31.11	18.26	10	11897	879	63476236
Blood test abnormal	29.41	18.26	24	11883	15605	63461510
Bone formation decreased	29.33	18.26	6	11901	83	63477032
Neoplasm progression	29.05	18.26	35	11872	36393	63440722
Osteolysis	28.92	18.26	13	11894	2861	63474254
Pneumonia influenzal	28.29	18.26	11	11896	1686	63475429
Tooth abscess	28.20	18.26	23	11884	14946	63462169
Blood potassium increased	28.08	18.26	25	11882	18284	63458831
Tumour marker increased	27.77	18.26	15	11892	4900	63472215
Contraindicated product administered	27.58	18.26	4	11903	217644	63259471
Hyperbaric oxygen therapy	27.28	18.26	5	11902	37	63477078
Mucosal inflammation	26.42	18.26	38	11869	46890	63430225
Body temperature decreased	25.86	18.26	25	11882	20294	63456821
Tooth disorder	25.70	18.26	29	11878	28128	63448987
Breast cancer	25.53	18.26	38	11869	48345	63428770
Blood parathyroid hormone increased	25.15	18.26	12	11895	3026	63474089
Wound dehiscence	25.05	18.26	14	11893	4889	63472226
Bone fistula	24.59	18.26	5	11902	67	63477048
Toxicity to various agents	24.38	18.26	8	11899	247242	63229873
Feeling cold	24.22	18.26	26	11881	23862	63453253
Arthropathy	24.22	18.26	7	11900	234785	63242330
Tumour lysis syndrome	23.98	18.26	17	11890	8973	63468142
Muscle spasms	23.97	18.26	74	11833	156076	63321039
Callus formation delayed	23.89	18.26	4	11903	16	63477099
Gastritis	23.68	18.26	32	11875	37271	63439844
Therapeutic product effect decreased	23.46	18.26	4	11903	193183	63283932
Aspergilloma	22.97	18.26	6	11901	252	63476863
Condition aggravated	22.93	18.26	25	11882	402192	63074923
Joint swelling	22.69	18.26	17	11890	327649	63149466
Immunodeficiency	22.23	18.26	23	11884	20231	63456884
Oedema peripheral	22.19	18.26	82	11825	189429	63287686
Rheumatoid arthritis	22.06	18.26	10	11897	253809	63223306
Musculoskeletal stiffness	22.03	18.26	4	11903	184614	63292501
Infusion site thrombosis	21.24	18.26	5	11902	136	63476979
Neutrophil count decreased	21.20	18.26	38	11869	56368	63420747
Metastases to liver	20.98	18.26	24	11883	23615	63453500
Gingival swelling	20.91	18.26	12	11895	4406	63472709
Product dose omission issue	20.72	18.26	9	11898	234304	63242811
Lymphatic disorder	20.66	18.26	6	11901	375	63476740
Oral surgery	20.58	18.26	8	11899	1226	63475889
Tumour marker abnormal	20.56	18.26	6	11901	381	63476734
Disease progression	20.55	18.26	60	11847	122698	63354417
Neuropathy peripheral	20.43	18.26	57	11850	113610	63363505
Feeling hot	20.32	18.26	35	11872	50319	63426796
Maternal exposure during pregnancy	20.19	18.26	8	11899	220054	63257061
Femoral neck fracture	20.19	18.26	15	11892	8508	63468607
Water intoxication	19.98	18.26	6	11901	421	63476694
Drug interaction	19.95	18.26	9	11898	229122	63247993
Periodontal destruction	19.80	18.26	3	11904	5	63477110
Osteomyelitis chronic	19.68	18.26	6	11901	443	63476672
Focal segmental glomerulosclerosis	19.23	18.26	8	11899	1460	63475655
Discomfort	19.18	18.26	4	11903	167370	63309745
Hepatic enzyme increased	19.15	18.26	7	11900	202321	63274794
Computerised tomogram abnormal	19.09	18.26	9	11898	2208	63474907
Blood calcium increased	18.96	18.26	15	11892	9335	63467780
Purulence	18.69	18.26	8	11899	1566	63475549

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Osteonecrosis	430.41	19.58	145	6487	14745	34935554
Osteonecrosis of jaw	294.48	19.58	115	6517	17774	34932525
Tooth extraction	164.29	19.58	53	6579	4675	34945624
Bone disorder	157.74	19.58	55	6577	6160	34944139
Plasma cell myeloma	153.92	19.58	97	6535	41940	34908359
Bone debridement	104.83	19.58	20	6612	186	34950113
Pain in jaw	79.53	19.58	42	6590	12998	34937301
Sequestrectomy	78.19	19.58	16	6616	219	34950080
Exposed bone in jaw	77.08	19.58	23	6609	1563	34948736
Debridement	75.40	19.58	20	6612	883	34949416
Atypical femur fracture	72.59	19.58	16	6616	318	34949981
Actinomycosis	61.64	19.58	15	6617	466	34949833
Hypercalcaemia	59.79	19.58	37	6595	15431	34934868
Osteomyelitis	58.36	19.58	37	6595	16099	34934200
Nephrocalcinosis	57.20	19.58	15	6617	633	34949666
Hyperbaric oxygen therapy	56.45	19.58	9	6623	24	34950275
Tibia fracture	52.29	19.58	17	6615	1533	34948766
Neuropathy peripheral	50.23	19.58	70	6562	83193	34867106
Femur fracture	49.05	19.58	26	6606	8098	34942201
Acute generalised exanthematous pustulosis	47.57	19.58	24	6608	6752	34943547
Hypocalcaemia	42.69	19.58	36	6596	24253	34926046
Purulent discharge	42.10	19.58	17	6615	2846	34947453
Impaired healing	38.36	19.58	28	6604	15306	34934993
Jaw fracture	37.30	19.58	12	6620	1046	34949253
Hepatitis B	35.70	19.58	19	6613	5964	34944335
Bone lesion excision	35.50	19.58	5	6627	3	34950296
Bone sequestrum	35.18	19.58	10	6622	572	34949727
Stress fracture	30.42	19.58	10	6622	933	34949366
Foot fracture	30.14	19.58	16	6616	4995	34945304
Jaw operation	29.36	19.58	7	6625	199	34950100
Pancytopenia	26.70	19.58	57	6575	95100	34855199
Fistula	25.51	19.58	16	6616	6824	34943475
Pustular psoriasis	24.99	19.58	10	6622	1635	34948664
Wound closure	24.26	19.58	5	6627	71	34950228
Deep vein thrombosis	24.26	19.58	44	6588	65204	34885095
Carcinoid tumour	23.39	19.58	6	6626	232	34950067
Bone swelling	22.88	19.58	6	6626	253	34950046
Jaw disorder	22.30	19.58	10	6622	2165	34948134
Bone lesion	22.28	19.58	11	6621	2952	34947347
CSF white blood cell count decreased	21.97	19.58	4	6628	28	34950271
Drug interaction	21.53	19.58	8	6624	225938	34724361
Chronic fatigue syndrome	20.75	19.58	6	6626	365	34949934
Maxillofacial operation	20.63	19.58	3	6629	3	34950296
Pneumonia	19.91	19.58	127	6505	362500	34587799
Bone pain	19.87	19.58	22	6610	20664	34929635
Extraskeletal ossification	19.81	19.58	4	6628	51	34950248
CSF white blood cell count increased	19.60	19.58	4	6628	54	34950245

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Osteonecrosis	978.58	16.96	324	15023	30771	79698270
Osteonecrosis of jaw	970.94	16.96	350	14997	42876	79686165
Tooth extraction	395.65	16.96	127	15220	10868	79718173
Bone disorder	388.42	16.96	144	15203	18969	79710072
Plasma cell myeloma	274.22	16.96	154	15193	53105	79675936
Bone debridement	248.58	16.96	47	15300	408	79728633
Sequestrectomy	224.29	16.96	48	15299	814	79728227
Debridement	185.65	16.96	47	15300	1698	79727343
Actinomycosis	169.24	16.96	40	15307	1079	79727962
Atypical femur fracture	162.57	16.96	54	15293	5135	79723906
Pain in jaw	151.27	16.96	100	15247	46051	79682990
Osteomyelitis	142.37	16.96	85	15262	32780	79696261
Bone sequestrum	140.17	16.96	35	15312	1194	79727847
Exposed bone in jaw	129.79	16.96	42	15305	3678	79725363
Metastases to bone	121.19	16.96	69	15278	24358	79704683
Malignant neoplasm progression	118.02	16.96	138	15209	135852	79593189
Infusion site coldness	113.81	16.96	22	15325	217	79728824
Impaired healing	113.40	16.96	110	15237	87545	79641496
Femur fracture	108.22	16.96	76	15271	38576	79690465
Gamma-glutamyltransferase decreased	103.40	16.96	22	15325	362	79728679
Hypocalcaemia	99.32	16.96	80	15267	49844	79679197
Bone pain	93.64	16.96	81	15266	55661	79673380
Bone lesion excision	89.14	16.96	14	15333	32	79729009
Hyperbaric oxygen therapy	84.96	16.96	14	15333	48	79728993
Infusion site induration	79.71	16.96	22	15325	1113	79727928
Jaw operation	76.80	16.96	20	15327	809	79728232
Hypercalcaemia	73.09	16.96	60	15287	38370	79690671
Fistula	70.83	16.96	39	15308	12901	79716140
Stress fracture	69.88	16.96	31	15316	6449	79722592
Jaw disorder	67.33	16.96	28	15319	4978	79724063
Post-traumatic neck syndrome	66.42	16.96	22	15325	2072	79726969
Cardiac output decreased	61.07	16.96	20	15327	1818	79727223
Nephrocalcinosis	60.83	16.96	19	15328	1483	79727558
Vein disorder	59.80	16.96	26	15321	5156	79723885
Wound closure	58.90	16.96	12	15335	158	79728883
Osteotomy	58.61	16.96	13	15334	262	79728779
Wound treatment	57.38	16.96	12	15335	181	79728860
Vasodilatation	57.36	16.96	22	15325	3169	79725872
Toothache	55.26	16.96	39	15308	19931	79709110
Infusion site haemorrhage	54.09	16.96	22	15325	3698	79725343
Bone lesion	50.30	16.96	24	15323	5895	79723146
Pathological fracture	47.56	16.96	28	15319	10509	79718532
Drug interaction	47.25	16.96	11	15336	415172	79313869
Purulent discharge	43.87	16.96	22	15325	6017	79723024
Tibia fracture	43.32	16.96	21	15326	5340	79723701
Mean cell haemoglobin decreased	43.24	16.96	22	15325	6202	79722839
Urine odour abnormal	43.08	16.96	22	15325	6251	79722790
Jaw fracture	41.00	16.96	17	15330	3000	79726041
Toxicity to various agents	40.95	16.96	15	15332	421525	79307516
Spinal pain	40.14	16.96	29	15318	15363	79713678
Osteitis	39.76	16.96	18	15329	3925	79725116
Abscess jaw	38.55	16.96	14	15333	1733	79727308
Neuropathy peripheral	38.04	16.96	84	15263	141221	79587820
Retinal detachment	37.65	16.96	23	15324	9224	79719817
Osteolysis	37.50	16.96	18	15329	4480	79724561
Peripheral coldness	36.96	16.96	28	15319	15942	79713099
Osteosclerosis	36.51	16.96	17	15330	3954	79725087
Pneumonia influenzal	34.91	16.96	15	15332	2889	79726152
Maxillofacial operation	33.84	16.96	5	15342	6	79729035
Blood parathyroid hormone increased	32.46	16.96	15	15332	3430	79725611
Hepatitis B	32.09	16.96	20	15327	8312	79720729
Body temperature decreased	31.87	16.96	35	15312	32110	79696931
Metastases to skin	31.29	16.96	12	15335	1727	79727314
Adenocarcinoma of colon	31.15	16.96	17	15330	5524	79723517
Foot fracture	31.08	16.96	29	15318	21952	79707089
Incontinence	30.95	16.96	24	15323	14140	79714901
Tooth disorder	30.33	16.96	31	15316	26202	79702839
Skin sensitisation	29.75	16.96	10	15337	985	79728056
Poor venous access	29.70	16.96	26	15321	18123	79710918
Bone fistula	28.91	16.96	6	15341	87	79728954
Osteomyelitis chronic	28.90	16.96	9	15338	695	79728346
Acute generalised exanthematous pustulosis	28.80	16.96	25	15322	17229	79711812
Oral surgery	28.58	16.96	10	15337	1111	79727930
Dental operation	28.23	16.96	10	15337	1152	79727889
Blood creatinine decreased	28.17	16.96	18	15329	7807	79721234
Tooth abscess	28.10	16.96	24	15323	16186	79712855
Muscle spasms	26.61	16.96	84	15263	174646	79554395
Tumour marker increased	26.52	16.96	14	15333	4258	79724783
Blood test abnormal	26.27	16.96	24	15323	17686	79711355
Neoplasm progression	25.64	16.96	40	15307	51642	79677399
Gingival swelling	25.52	16.96	14	15333	4595	79724446
Product dose omission issue	25.42	16.96	8	15339	247529	79481512
Tumour lysis syndrome	25.37	16.96	27	15320	23912	79705129
Plastic surgery	24.39	16.96	5	15342	68	79728973
Metastases to lung	23.84	16.96	23	15324	18140	79710901
Periodontal destruction	23.79	16.96	4	15343	16	79729025
Callus formation delayed	23.79	16.96	4	15343	16	79729025
Wound dehiscence	23.32	16.96	15	15332	6580	79722461
Stem cell transplant	22.60	16.96	12	15335	3692	79725349
Blood potassium increased	22.55	16.96	28	15319	29247	79699794
Purulence	22.20	16.96	10	15337	2155	79726886
Arteriovenous fistula thrombosis	22.19	16.96	7	15340	564	79728477
Immunodeficiency	22.10	16.96	24	15323	21744	79707297
Tumour marker abnormal	22.04	16.96	6	15341	288	79728753
Metastases to liver	21.68	16.96	27	15320	28287	79700754
Oedema peripheral	21.62	16.96	101	15246	252187	79476854
Gingival erythema	21.33	16.96	7	15340	640	79728401
Lymphatic disorder	21.18	16.96	6	15341	334	79728707
Bone swelling	21.09	16.96	9	15338	1705	79727336
Oral cavity fistula	20.72	16.96	7	15340	700	79728341
Condition aggravated	20.47	16.96	41	15306	501083	79227958
Hepatic enzyme increased	20.42	16.96	5	15342	182605	79546436
Contraindicated product administered	20.40	16.96	3	15344	157535	79571506
Deep vein thrombosis	20.14	16.96	60	15287	120859	79608182
Hypophagia	19.63	16.96	33	15314	45334	79683707
Gastritis	19.57	16.96	34	15313	47959	79681082
Actinomycotic skin infection	19.37	16.96	3	15344	6	79729035
Blood calcium increased	19.27	16.96	16	15331	10384	79718657
Gingivitis	19.09	16.96	15	15332	9006	79720035
Overdose	18.82	16.96	6	15341	184200	79544841
Feeling cold	18.26	16.96	25	15322	28704	79700337
Computerised tomogram abnormal	17.89	16.96	10	15337	3403	79725638
Monoclonal immunoglobulin present	17.80	16.96	7	15340	1078	79727963
Aspergilloma	17.55	16.96	6	15341	622	79728419
Therapeutic product effect decreased	17.35	16.96	5	15342	163858	79565183
Joint swelling	17.31	16.96	18	15329	288628	79440413
Post procedural diarrhoea	17.14	16.96	6	15341	668	79728373

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	M05BA03	MUSCULO-SKELETAL SYSTEM DRUGS FOR TREATMENT OF BONE DISEASES DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION Bisphosphonates
FDA CS	M0006519	Diphosphonates
FDA EPC	N0000175579	Bisphosphonate
MeSH PA	D050071	Bone Density Conservation Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Osteitis deformans	indication	2089002	DOID:5408
Humoral hypercalcemia of malignancy	indication	47709007
Osteolytic Lesions of Multiple Myeloma	indication
Osteolytic Bone Metastases of Breast Cancer	indication
Drug-induced osteoporosis	off-label use	14651005
Prevention of Glucocorticoid-Induced Osteoporosis	off-label use
Bone Metastases	off-label use
Hypophosphatemia	contraindication	4996001
Hypocalcemia	contraindication	5291005
Hypovolemia	contraindication	28560003
Dehydration	contraindication	34095006
Periodontitis	contraindication	41565005	DOID:824
Hypokalemia	contraindication	43339004
Kidney disease	contraindication	90708001	DOID:557
Hypomagnesemia	contraindication	190855004
Pregnancy, function	contraindication	289908002
Aseptic necrosis of bone of jaw	contraindication	441809006
Thyroid Surgery	contraindication
Invasive Dental Procedure	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	0.71	acidic
pKa2	4.78	acidic
pKa3	5.76	acidic
pKa4	9.83	acidic
pKa5	13.04	acidic
pKa6	11.49	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Farnesyl pyrophosphate synthase	Enzyme	P14324	FPPS_HUMAN	INHIBITOR	Ki	7.25	CHEMBL	CHEMBL
Farnesyl pyrophosphate synthase	Enzyme		Q0GKD7_LEIDO		Ki	6.72	CHEMBL
Hypoxanthine-guanine phosphoribosyltransferase	Enzyme		HPRT_TRYBB		Ki	4.30	CHEMBL

External reference:

ID	Source
D00941	KEGG_DRUG
109552-15-0	SECONDARY_CAS_RN
4020311	VANDF
4020543	VANDF
C3714572	UMLSCUI
CHEBI:7903	CHEBI
210	PDB_CHEM_ID
CHEMBL834	ChEMBL_ID
DB00282	DRUGBANK_ID
CHEMBL676	ChEMBL_ID
CHEMBL3989401	ChEMBL_ID
4674	PUBCHEM_CID
7259	IUPHAR_LIGAND_ID
6305	INN_ID
OYY3447OMC	UNII
105443	RXNORM
42496	MMSL
5226	MMSL
d00601	MMSL
003616	NDDF
005066	NDDF
396032007	SNOMEDCT_US
420442001	SNOMEDCT_US
772820008	SNOMEDCT_US
96288007	SNOMEDCT_US
D000077268	MESH_DESCRIPTOR_UI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Pamidronate Disodium	HUMAN PRESCRIPTION DRUG LABEL	1	59923-601	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	3 mg	INTRAVENOUS	ANDA	24 sections
Pamidronate Disodium	HUMAN PRESCRIPTION DRUG LABEL	1	59923-602	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	6 mg	INTRAVENOUS	ANDA	24 sections
Pamidronate Disodium	HUMAN PRESCRIPTION DRUG LABEL	1	59923-603	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	9 mg	INTRAVENOUS	ANDA	24 sections
Pamidronate Disodium	HUMAN PRESCRIPTION DRUG LABEL	1	61703-324	INJECTION, SOLUTION	3 mg	INTRAVENOUS	ANDA	12 sections
Pamidronate Disodium	HUMAN PRESCRIPTION DRUG LABEL	1	61703-325	INJECTION, SOLUTION	6 mg	INTRAVENOUS	ANDA	12 sections
Pamidronate Disodium	HUMAN PRESCRIPTION DRUG LABEL	1	61703-326	INJECTION, SOLUTION	9 mg	INTRAVENOUS	ANDA	12 sections
Pamidronate Disodium	HUMAN PRESCRIPTION DRUG LABEL	1	67457-430	INJECTION	3 mg	INTRAVENOUS	ANDA	20 sections
Pamidronate Disodium	HUMAN PRESCRIPTION DRUG LABEL	1	67457-446	INJECTION	9 mg	INTRAVENOUS	ANDA	20 sections